Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow

Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.

Deals Research & Development

Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D

After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.

Business Strategies Drug Approval Standards

Top 10 Best-Selling Drugs Of Q2 2023: COVID-19 Out, HPV In

The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.

Sales & Earnings Market Intelligence

A Closer Look: Commercial Impact For Drugs Up For Medicare Price Negotiation

An infographic looking at commercial factors for the 10 drugs chosen for Medicare price negotiation in 2026 under the Inflation Reduction Act (IRA). The graphics below review the valuations of these drugs, both past and forecast, as well as their relative contributions to the top-lines of the companies that own them.

Market Access Medicare

Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List

The Class of ’26 of Medicare Price Negotiation University is now on stage. Our infographic profiles who they are and where they come from, breaking down the $50.5B in gross annual Part D spending, about 20% of the total.

United States Intellectual Property

Piling On: AstraZeneca Files Sixth Manufacturer Lawsuit Against Medicare Negotiation Program

Firm leans into allegations that the US government violated the Administrative Procedures Act in implementing the program. More legal actions are expected from industry once CMS announces the first list of drugs subject to negotiation. Our lawsuit tracker will keep you apprised.

Reimbursement Pricing Debate

Industry's Suits Against Medicare Price Negotiation: Consolidation And Expansion

With a new suit from Boehringer Ingelheim and a consolidated schedule for other cases, the legal threats to the US Medicare drug price negotiation program mandated under the Inflation Reduction Act (IRA) become clearer. Our tracker keeps you apprised of the latest developments.

Reimbursement Policy

Korean Firms Readying To Compete In Global GLP-1 Obesity Space

With Hanmi's progress in changing the main indication of its GLP-1 contender efpeglenatide to obesity, Scrip takes an infographic look at what other Korean firms are doing in both this indication and elsewhere in the GLP-1 space. 

South Korea Clinical Trials

Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It

Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, Scrip offers a baker's dozen of possible drugs.

Medicare Reimbursement

Titans Of Pharma: Pfizer’s Bourla Tops Big Pharma CEO Compensation League

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Leadership Companies

Tracking Industry’s Lawsuits Against IRA’s Medicare Price Negotiations

Industry stakeholders have filed various lawsuits against the US government, attempting to slow down or block the implementation of a new Medicare drug price negotiation program. Scrip's new chart tracks the developments.

Medicare Legal Issues

Top 10 Best-Selling Drugs Of Q1 2023: Keytruda Topples Humira

A review of the top-selling drugs of the first quarter of 2023 demonstrate the declining turnover from products to treat or prevent COVID-19, as well as a precipitative drop by Humira. Merck & Co’s PD-1 inhibitor Keytruda grew strongly, and Novo Nordisk’s injectable diabetes drug Ozempic burst into the top 10 ranks.

Market Intelligence Sales & Earnings

Despite Pfizer/Seagen’s Splash, Deals Are Staying Small

Although late 2022 and early 2023 saw a few large transactions, a look at deal activity in the first half of the year shows bolt-on M&A remains in vogue for biopharma. Alliances are down from first half 2022.

Deals M & A

As Ozempic, Mounjaro Grab Share, Can Metformin Get A Leg-Up From Long COVID?

Diabetes and obesity products like Ozempic/Wegovy and Mounjaro are gaining share at the expense of metformin and SGLT-2 inhibitors. Scrip looks at data on prescription shifts in the US while examining if metformin remains attractive and whether a recent study showing efficacy in long COVID treatment could help

Commercial Coronavirus COVID-19

Is The US Less Attractive Than India? A Proxy Comparison Via Strides And Torrent

Scrip examines Torrent Pharma and Strides Pharma’s divergent strategies and Q4 financial performance in the US and India while presenting an infographic to compare market-wise metrics

Commercial Business Strategies

India Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change

Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.

Research & Development Clinical Trials
See All